{"Clinical Trial ID": "NCT01026142", "Intervention": ["INTERVENTION 1:", "A: Capecitabine + Trastuzumab", "- Capecitabine [Xeloda]: 1250 mg/m2 twice daily for 14 days every 3 weeks Trastuzumab [Herceptin]: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks.", "INTERVENTION 2:", "B: Capecitabine + Trastuzumab + Pertuzumab", "Pertuzumab [Perjeta]: 840 mg iv loading, then 420 mg iv every 3 weeks Trastuzumab [Herceptin]: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks Trastuzumab [Herceptin]: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks."], "Eligibility": ["Incorporation criteria:", "Female adults >/=18 years", "HER2 metastatic positive breast cancer", "The Eastern Cooperative Oncology Group (ECOG) has achieved progress 0 or 1", "\u2022 Disease progression during or after treatment with trastuzumab for first-line metastatic breast cancer (trastuzumab should have been part of the last previous treatment)", "Previous treatment with a treatment containing taxane", "Left ventricular ejection fraction (VEF) >/=50 percent", "For women of childbearing potential, agree to use highly effective non-hormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner. Contraception should continue throughout the duration of the study treatment and for at least 6 months after the last dose of the study treatment.", "- Exclusion criteria:", "Previous treatment with pertuzumab or capecitabine", "- Concomitant treatment with another experimental medicine", "\u2022 Concomitant immunotherapy or hormonal cancer treatment", "(e.g., active infection, uncontrolled hypertension, cardiovascular disease)", "- Central nervous system (CNS) metastases, which are not well controlled", "History of exposure to the cumulative dose of anthracycline equivalent to 360mg/m2", "History of congestive heart failure of any New York Heart Association criteria, or severe cardiac arrhythmia requiring treatment", "\u2022 History of myocardial infarction within 6 months prior to randomization", "The history of FEVL decreased to less than 50% during or after treatment with trastuzumab or any other cardiac toxicity during previous treatment with trastuzumab, which necessitated discontinuation of trastuzumab.", "\u2022 History of another cancer that may affect compliance or interpretation of results", "Inadequate function of organs", "Pregnant or lactating women", "Life expectancy < 12 weeks"], "Results": ["Performance measures:", "Survival without progression (independent assessment)", "The primary endpoint was analyzed after approximately 337 PFS events evaluated by the PFS.", "Timing: Assessment of tumours every 9 weeks from randomization to week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of an alternative anticancer drug or death (up to 5.5 years).", "Results 1:", "Title of arm/group: A: Capecitabine + Trastuzumab", "Description of the arm/group: Capecitabine [Xeloda]: 1250 mg/m2 twice daily for 14 days every 3 weeks Trastuzumab [Herceptin]: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks.", "Total number of participants analysed: 224", "Median (95% confidence interval)", "Unit of measure: month 9.0 (8-10)", "Results 2:", "Title of arm/group: B: Capecitabine + Trastuzumab + Pertuzumab", "Description of the arm/group: Capecitabine [Xeloda]: 1000 mg/m2 twice daily for 14 days every 3 weeks Pertuzumab [Perjeta]: 840 mg iv loading, then 420 mg iv every 3 weeks Trastuzumab [Herceptin]: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks.", "Total number of participants analysed: 228", "Median (95% confidence interval)", "Unit of measure: months 11.1 (9-13)"], "Adverse Events": ["Undesirable Events 1:", "Total: 53/218 (24.31%)", "Febrile Neutropenia 2/218 (0.92%)", "Neutropenia 2/218 (0.92%)", "Anemia 1/218 (0.46%)", "Thrombocytopenia 1/218 (0.46%)", "Pancytopenia 0/218 (0.00 %)", "Left ventricular function 4/218 (1.83%)", "Atrial fibrillation 0/218 (0.00 %)", "Angina Instable 0/218 (0.00 %)", "- Coronary arteriospasm 1/218 (0.46%)", "- Cardiac arrest 1/218 (0.46%)", "Adverse Events 2:", "Total: 58/228 (25.44 per cent)", "Febrile Neutropenia 1/228 (0.44%)", "Neutropenia 1/228 (0.44%)", "Anemia 0/228 (0.00 %)", "Thrombocytopenia 1/228 (0.44%)", "Pancytopenia 1/228 (0.44%)", "13/228 (5.70%) left ventricular dysfunction", "2/228 (0.88%) Atrial fibrillation", "Angina Instable 1/228 (0.44%)", "- Arteriospasm Coronary 0/228 (0.00 %)", "- Cardiac arrest 0/228 (0.00 %)"]}